These stocks offer great dividends and more.Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper.Three Motley Fool contributors have found stocks with mouthwatering dividends that you can buy right now. Here's why they picked Gilead Sciences (GILD 1.33%), Organon (OGN 0.39%), and Pfizer (PFE -0.76%).A safe, reliable dividend payerProsper Junior Bakiny (Gilead Sciences): When looking for so ...

Gilead Sciences, Inc. (NASDAQ:GILD) Jefferies 2024 Global Healthcare Conference June 5, 2024 11:00 AM ET Company Participants Merdad Parsey - Chief Medical Officer Conference Call Participants Michael Yee - Jefferies Michael Yee I am very happy to have up here with us Chief Medical Officer of Gilead, Merdad Parsey. It's great to have you with us fresh off of four or five days of ASCO. So lots to talk about. Question-and-Answer Session Q - Michael Yee Maybe just opening up for Gilead, I'd love to just have y ...

Gilead Sciences, Inc. (NASDAQ:GILD) Jefferies 2024 Global Healthcare Conference June 5, 2024 11:00 AM ET Company Participants Merdad Parsey - Chief Medical Officer Conference Call Participants Michael Yee - Jefferies Michael Yee I am very happy to have up here with us Chief Medical Officer of Gilead, Merdad Parsey. It's great to have you with us fresh off of four or five days of ASCO. So lots to talk about. Question-and-Answer Session Q - Michael Yee Maybe just opening up for Gilead, I'd love to just have y ...

Gilead Sciences, Inc. (GILD) and partner Arcus Biosciences, Inc. (RCUS) announce new data from Cohort B of the ARC-9 study.ARC-9 is a phase Ib/II study evaluating the safety and efficacy of etrumadenant (E), a dual A2a/A2b adenosine receptor antagonist, plus anti-PD-1 antibody zimberelimab (Z), FOLFOX and bevacizumab (“EZFB”), in three cohorts of patients suffering from metastatic colorectal cancer (mCRC).Cohort B of ARC-9 randomized 112 patients with comparable baseline characteristics between two arms: EZ ...

ffikretow/iStock via Getty Images My last article about Gilead Sciences, Inc. (NASDAQ:GILD) was published in August 2023 and once again the stock declined while the overall market outperformed. Back then, the stock was trading for $77, and Gilead Sciences declined 12% while the S&P 500 (SPY) increased 20% in the same timeframe. But the story that Gilead Sciences underperformed the S&P 500 is not news at this point. Gilead Sciences underperformed the S&P 500 basically on every timeframe - 6 months, 1 year, 3 ...

Olivier Le Moal I will say this pick is based more on a hunch (honed over 37 years of trading) than any concrete news catalyst or technical trading evidence. I bought a stake in Gilead Sciences (NASDAQ:GILD) recently on the view a bear market and recession will eventually force investors to move money into defensive ideas like pharmaceuticals. This group has an excellent history of witnessing massive flight-to-safety money flows during stressful periods overall on Wall Street. Specifically, Gilead has p ...

Yuji SakaiMy goal is to track the 500 world's best companies, and we use a few lists as a proxy. Every dividend aristocrat and champion, including foreign ones (25-plus year dividend growth streaks). Top 100 holdings in VIG (aristocrat and future aristocrat ETF). Top 100 holdings in SCHD (gold standard high-yield blue-chip ETF). Top 100 holdings in IWY (gold standard growth ETF). A recent addition is Gilead Sciences (NASDAQ:GILD), which many people have asked me about recently, as the yield has risen ...

While it tends to fly under the radar for many people, the biotech industry has seen a resurgence in investor interest over the last couple of years. While there could be several reasons for this, such as the COVID-19 pandemic bringing the value of biotechnology to the forefront or even the expansion of education in the biosciences, the fact remains – biotech is getting more attention than ever before. Nowadays, both institutional and retail investors are discussing which are the best biotech stocks to buy ...

Gilead Sciences, Inc. (GILD) announced positive interim results from the ongoing ASSURE study on pipeline candidate seladelpar. ASSURE is an open-label study evaluating the long-term safety and efficacy of seladelpar, a once-daily potent and selective peroxisome proliferator-activated receptor (PPAR) delta agonist or delpar. Seladelpar is a first-in-class oral, selective PPAR-delta agonist or delpar is being evaluated for treating primary biliary cholangitis (PBC). The study enrolled adult patients with PBC ...

Gilead Sciences, Inc. (NASDAQ:GILD) RBC Capital Markets Global Healthcare Conference May 15, 2024 10:30 AM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Brian Abrahams Senior Biotech Analyst at RBC Capital Markets. We're really pleased to have our next presenting company, Gilead, represented by their Chief Commercial Officer, Johanna Mercier. Johanna, thanks again for joining us. Johanna Mercier Thanks, Brian, and hi, eve ...